![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TANOX BEGINS TRIAL OF ANTI-IL-13 AGENT FOR TREATING ASTHMA
TANOX BEGINS TRIAL OF ANTI-IL-13 AGENT FOR TREATING ASTHMA
October 30, 2006
Tanox has begun dosing in a Phase I clinical trial of TNX-650, a humanized monoclonal antibody being evaluated as a potential treatment for moderate-to-severe asthma.
The trial is a randomized, double-blind, placebo-controlled, dose-escalation study of the safety, tolerability and pharmacokinetics of single doses of TNX-650 in healthy volunteers. A total of 32 subjects will be enrolled in four cohorts in the study, which is being conducted at a single site in the U.S.
TNX-650 targets Interleukin 13 (IL-13). Preclinical studies indicate that IL-13 is a key mediator of asthma responses, including airway inflammation, obstruction and hyper-reactivity. TNX-650, which has a mechanism of action different from currently available asthma treatments, has the potential to be a therapeutic option for patients whose disease is not well-controlled and for non-allergic asthmatics.
Tanox is also evaluating the anti-IL-13 effect of TNX-650 as a potential treatment for Hodgkin's lymphoma in an ongoing Phase I clinical trial.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct